Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 337-343

  Cairncross, Gregory ^a   Wang, Meihua ^d   Shaw, Edward ^e   Jenkins, Robert ^f   Brachman, David ^g   Buckner, Jan ^f   Fink, Karen ^h   Souhami, Luis ^b   Laperriere, Normand ^c   Curran, Walter ⁱ   Mehta, Minesh ^j  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d RADIATION THERAPY ONCOLOGY GROUP   (United States)

^e WAKE FOREST UNIVERSITY   (United States)

^f MAYO CLINIC   (United States)

^g Arizona Oncology Services   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ EMORY UNIVERSITY   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; OLIGODENDROGLIOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE-FREE SURVIVAL; GENE DELETION; HUMANS; KAPLAN-MEIER ESTIMATE; LOMUSTINE; OLIGODENDROGLIOMA; PROCARBAZINE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; TIME; VINCRISTINE;

EID: 84873338121     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.2674     Document Type: Article

References (33)

1. Louis DN, Ohgaki H, Weistler OD, et al (eds) WHO Classification of Tumors of the Central Nervous System, 4th ed. Lyon, France, IARC Press, 2007
2. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
3. Noushmehr H, Weisenberger DJ, Diefes K, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17:510-522, 2010
4. Xu W, Yang H, Liu Y, et al: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17-30, 2010
5. Reifenberger J, Reifenberger G, Liu L, et al Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175-1190, 1994 (Pubitemid 24345665)
6. Bettegowda C, Agrawal N, Jiao Y, et al Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453-1455, 2011
7. Yip S, Butterfield YS, Morozova O, et al: Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226:7-16, 2012
8. Bourne TD, Schiff D: Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 6:695-701, 2010
9. Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 359:492-507, 2008
10. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
11. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360-364, 1988 (Pubitemid 18098242)
12. Kim L, Hochberg FH, Thornton AF, et al: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85:602-607, 1992 (Pubitemid 26315193)
13. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013-2021, 1994
14. van den Bent MJ, Kros JM, Heimans JJ, et al: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy: Dutch Neuro-Oncology Group. Neurology 51:1140-1145, 1998 (Pubitemid 28473415)
15. Macdonald DR, Gaspar LE, Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27:573-574, 1990 (Pubitemid 20149980)
16. Paleologos NA, Macdonald DR, Vick NA, et al: Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53:1141-1143, 1999 (Pubitemid 29442142)
17. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998 (Pubitemid 28482012)
18. Smith JS, Perry A, Borell TJ, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645, 2000 (Pubitemid 30078545)
19. Cairncross G, Berkey B, Shaw E, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006 (Pubitemid 46630566)
20. van den Bent MJ, Carpentier AF, Brandes AA, et al: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722, 2006 (Pubitemid 46630567)
21. Folstein MF, Folstein SE, McHugh PR: "Minimental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975
22. Mackworth N, Fobair P, Prados MD: Quality of life self-reports from 200 brain tumor patients: Comparisons with Karnofsky performance scores. J Neurooncol 14:243-253, 1992 (Pubitemid 23012159)
23. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
24. Wang M, Cairncross G, Shaw E, et al: Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation Therapy Oncology Group trial 9402. Int J Radiat Oncol Biol Phys 77:662-669, 2010
25. Wick W, Hartmann C, Engel C, et al: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874-5880, 2009
26. Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495-2499, 2002 (Pubitemid 34525735)
27. Chinot OL, Honore S, Dufour H, et al: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19:2449-2455, 2001 (Pubitemid 32391216)
28. van den Bent MJ, Taphoorn MJ, Brandes AA, et al: Phase II study of first line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for the Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525-2528, 2003 (Pubitemid 46606334)
29. Hoang-Xuan K, Capelle L, Kujas M, et al: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133-3138, 2004 (Pubitemid 41103727)
30. Lassman AB, Iwamoto FM, Cloughesy TF, et al: International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 13:649-659, 2011
31. Abrey LE, Louis DN, Paleologos NA, et al: A survey of practice patterns for anaplastic oligodendroglioma. Neuro Oncol 9:314-318, 2007 (Pubitemid 47169664)
32. Panageas KS, Iwamoto FM, Cloughesy TF, et al: Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol 14:761-767, 2012
33. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)